WEDNESDAY, March 20, 2024 (HealthDay Information) — For sufferers with mild-to-moderate COVID-19, viral load rebound and symptom rebound can happen after a normal five-day course of therapy with VV116 or nirmatrelvir-ritonavir, in keeping with a research revealed on-line March 13 in JAMA Community Open.
Zhitao Yang, M.D., from Ruijin Hospital in Shanghai, and colleagues carried out a randomized scientific trial involving adults with mild-to-moderate COVID-19 and inside 5 days of extreme acute respiratory syndrome coronavirus 2 an infection. Contributors had been randomly allotted to obtain VV116 or nirmatrelvir-ritonavir (165 and 180 sufferers, respectively) for 5 days.
The researchers discovered that viral load rebound occurred in 20.0 and 21.7 p.c of sufferers within the VV116 and nirmatrelvir-ritonavir teams, respectively. Symptom rebound occurred in 25.6 and 24.5 p.c of sufferers within the VV116 and nirmatrelvir-ritonavir teams, respectively. For twenty-four rebound circumstances, viral whole-genome sequencing confirmed the identical lineage at baseline and viral load rebound.
“Efficient therapy choices along with the drug per se, particularly the potential prolongation of therapy period, in addition to the interaction of viral an infection, host immunity, and antiviral therapy within the strategy of rebound, warrant investigation in future research,” the authors write.
VV116 and nirmatrelvir-ritonavir tablets had been offered by the Shanghai Junshi Biosciences.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.